Log in

NASDAQ:ICLR - Icon Stock Price, Forecast & News

$162.90
+1.50 (+0.93 %)
(As of 12/9/2019 01:24 AM ET)
Today's Range
$161.67
Now: $162.90
$163.42
50-Day Range
$140.06
MA: $152.30
$163.64
52-Week Range
$118.10
Now: $162.90
$165.13
Volume121,778 shs
Average Volume258,143 shs
Market Capitalization$8.79 billion
P/E Ratio25.90
Dividend YieldN/A
Beta0.71
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. Read More…

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ICLR
CUSIPN/A
Phone353-1291-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.60 billion
Cash Flow$7.68 per share
Book Value$25.09 per share

Profitability

Net Income$322.66 million

Miscellaneous

Employees13,670
Market Cap$8.79 billion
Next Earnings Date2/19/2020 (Estimated)
OptionableOptionable

Receive ICLR News and Ratings via Email

Sign-up to receive the latest news and ratings for ICLR and its competitors with MarketBeat's FREE daily newsletter.


Icon (NASDAQ:ICLR) Frequently Asked Questions

What is Icon's stock symbol?

Icon trades on the NASDAQ under the ticker symbol "ICLR."

How were Icon's earnings last quarter?

Icon Plc (NASDAQ:ICLR) released its quarterly earnings data on Wednesday, October, 23rd. The medical research company reported $1.74 earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of $1.74. The medical research company earned $710.40 million during the quarter, compared to analyst estimates of $709.75 million. Icon had a return on equity of 24.86% and a net margin of 13.16%. The business's revenue for the quarter was up 8.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.54 EPS. View Icon's Earnings History.

When is Icon's next earnings date?

Icon is scheduled to release their next quarterly earnings announcement on Wednesday, February 19th 2020. View Earnings Estimates for Icon.

What guidance has Icon issued on next quarter's earnings?

Icon updated its FY19 earnings guidance on Wednesday, October, 23rd. The company provided EPS guidance of $6.81-6.95 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.88. The company issued revenue guidance of $2.79-2.83 billion, compared to the consensus revenue estimate of $2.81 billion.

What price target have analysts set for ICLR?

8 analysts have issued twelve-month target prices for Icon's stock. Their forecasts range from $154.00 to $170.00. On average, they expect Icon's stock price to reach $162.57 in the next year. This suggests that the stock has a possible downside of 0.2%. View Analyst Price Targets for Icon.

What is the consensus analysts' recommendation for Icon?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Icon in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Icon.

Has Icon been receiving favorable news coverage?

News stories about ICLR stock have been trending very negative recently, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Icon earned a coverage optimism score of -3.0 on InfoTrie's scale. They also assigned news articles about the medical research company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Icon.

Are investors shorting Icon?

Icon saw a increase in short interest in November. As of November 15th, there was short interest totalling 862,400 shares, an increase of 34.4% from the October 31st total of 641,500 shares. Based on an average trading volume of 227,600 shares, the short-interest ratio is currently 3.8 days. Approximately 1.6% of the company's shares are short sold. View Icon's Current Options Chain.

Who are some of Icon's key competitors?

What other stocks do shareholders of Icon own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Icon investors own include Pfizer (PFE), Gilead Sciences (GILD), CVS Health (CVS), Mastercard (MA), Procter & Gamble (PG), Post (POST), Visa (V), Johnson & Johnson (JNJ), Amgen (AMGN) and Euronet Worldwide (EEFT).

Who are Icon's key executives?

Icon's management team includes the folowing people:
  • Dr. Steven A. Cutler, CEO & Director (Age 59)
  • Mr. Brendan Brennan, Chief Financial Officer (Age 40)
  • Jonathan Curtain, VP of Corp. Fin. & Investor Relations
  • Mr. Thomas O'Leary, Chief Information Officer
  • Mr. Diarmaid Cunningham, Chief Admin. Officer, Gen. Counsel, Exec. VP & Company Sec. (Age 44)

Who are Icon's major shareholders?

Icon's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include WCM Investment Management LLC (6.66%), Comgest Global Investors S.A.S. (2.83%), Massachusetts Financial Services Co. MA (2.58%), Boston Partners (2.51%), Stephens Investment Management Group LLC (1.05%) and SPF Beheer BV (0.96%).

Which major investors are selling Icon stock?

ICLR stock was sold by a variety of institutional investors in the last quarter, including Boston Partners, State Street Corp, Renaissance Group LLC, Man Group plc, Peregrine Capital Management LLC, Stephens Investment Management Group LLC, Russell Investments Group Ltd. and Systematic Financial Management LP.

Which major investors are buying Icon stock?

ICLR stock was bought by a variety of institutional investors in the last quarter, including Comgest Global Investors S.A.S., SPF Beheer BV, WCM Investment Management LLC, Massachusetts Financial Services Co. MA, Voloridge Investment Management LLC, California Public Employees Retirement System, Meritage Portfolio Management and Fisher Asset Management LLC.

How do I buy shares of Icon?

Shares of ICLR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Icon's stock price today?

One share of ICLR stock can currently be purchased for approximately $162.90.

How big of a company is Icon?

Icon has a market capitalization of $8.79 billion and generates $2.60 billion in revenue each year. The medical research company earns $322.66 million in net income (profit) each year or $6.29 on an earnings per share basis. Icon employs 13,670 workers across the globe.View Additional Information About Icon.

What is Icon's official website?

The official website for Icon is http://www.iconplc.com/.

How can I contact Icon?

Icon's mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The medical research company can be reached via phone at 353-1291-2000.


MarketBeat Community Rating for Icon (NASDAQ ICLR)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  505 (Vote Outperform)
Underperform Votes:  441 (Vote Underperform)
Total Votes:  946
MarketBeat's community ratings are surveys of what our community members think about Icon and other stocks. Vote "Outperform" if you believe ICLR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICLR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/9/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel